Carcinoma neuroendocrino de células pequeñas de esófago: reporte de caso y revisión bibliográfica

Johana Lipiejko; Ignacio Moratorio; Adrián Canavesi

doi:10.47892/rgp.2024.443.1678

Authors

Johana Lipiejko Clínica de Gastroenterología “Prof. Dra. Carolina Olano”, Montevideo, Uruguay; Hospital de Clínicas “Dr. Manuel Quintela”, Montevideo, Uruguay. https://orcid.org/0009-0005-6765-7415
Ignacio Moratorio Clínica de Gastroenterología “Prof. Dra. Carolina Olano”, Montevideo, Uruguay; Hospital de Clínicas “Dr. Manuel Quintela”, Montevideo, Uruguay. https://orcid.org/0000-0002-4661-7263
Adrián Canavesi Clínica de Gastroenterología “Prof. Dra. Carolina Olano”, Montevideo, Uruguay; Hospital de Clínicas “Dr. Manuel Quintela”, Montevideo, Uruguay. https://orcid.org/0000-0001-7761-7701

DOI:

https://doi.org/10.47892/rgp.2024.443.1678

Keywords:

Carcinoma, neuroendocrine, Esophagus, Dysphagia

Abstract

Oesophageal cancer corresponds to a malignant neoplasm with a poor prognosis. Neuroendocrine tumors of the esophagus are very rare, accounting for less than 2%. When clinically manifested by permanent, progressive dysphagia and general impact, they usually correspond to locally advanced tumors with a poor prognosis. We present the case of a 45-year-old man who attended medical attention for persistent and progressive dysphagia, who was diagnosed with neuroendocrine carcinoma of the oesophagus. The diagnosis was reached through endoscopy, revealing an extensive, vegetative and stenosing lesion occupying three-quarters of the oesophageal circumference. Histology confirmed the diagnosis of poorly differentiated small cell malignancy with positive immunohistochemistry for chromogranin A and synaptophysin. In light of the diagnosis of small cell neuroendocrine carcinoma of the oesophagus with locaregional extension, stage IV, palliative treatment with chemotherapy, radiotherapy and percutaneous endoscopic gastronomy was proposed, with a survival of only 6 months.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

World Health Organization. Cancer today [Internet]. Geneva: WHO; 2020 [citado el 3 de noviembre de 2023]. Disponible en: https://gco.iarc.fr/today/home

Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400-12. doi: 10.1016/S0140-6736(12)60643-6.

Taruselli R, Santiago P. Cáncer de esófago [Internet]. Montevideo: Universidad de la República; 2018 [citado el 3 de noviembre de 2023]. Disponible en: https://www.quirurgicab.hc.edu.uy/images/C%C3%A1ncer_de_es%C3%B3fago_CQFM.pdf

Raúl Méndez-Vivas W, Salazar-Chavoya N, Vázquez-Pelcastre R, Del M, Pereyra-Balmes C. Carcinoma neuroendocrino primario de esófago. Reporte de un caso y revisión de la literatura. Evid Med Invest Salud. 2014;7(3):139-42.

Uehara, T, Olmos JI, Rodríguez Catán J, Avagnina A, Antelo P, Waldbaum C, et al. Carcinoma neuroendocrino esofágico de células pequeñas. Acta Gastroenterol Latinoam. 2020;50(2):159-162.

Mendoza-Hayashida Y, Benites-Goñi H, Soto A. Carcinoma neuroendocrino de esófago: reporte de caso. Rev Gastroenterol Peru. 2018;38(3):293-6.

Ji A, Jin R, Zhang R, Li H. Primary small cell carcinoma of the esophagus: progression in the last decade. Ann Transl Med. 2020;8(7):502. doi: 10.21037/atm.2020.03.214.

Chin JL, O’Toole D. Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors. Clin Endosc. 2017;50(6):520-529. doi: 10.5946/ce.2017.181.

Lee CG, Lim YJ, Park SJ, Jang BI, Choi SR, Kim JK, et al. The clinical features and treatment modality of esophageal neuroendocrine tumors: a multicenter study in Korea. BMC Cancer. 2014;14(1):569. doi: 10.1186/1471-2407-14-569.

Vos B, Rozema T, Miller RC, Hendlisz A, Luc J, Khanfir K, et al. Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study. Dis Esophagus. 2011;24(4):258-64. doi: 10.1111/j.1442-2050.2010.01133.x.

Wong AT, Shao M, Rineer J, Osborn V, Schwartz D, Schreiber D. Treatment and survival outcomes of small cell carcinoma of the esophagus: an analysis of the National Cancer Data Base. Dis Esophagus. 2017;30(2):1-5. doi: 10.1111/dote.12487.

Wu I-Chen, Chu YY, Wang YK, Tsai CL, Lin JC, Kuo CH, et al. Clinicopathological features and outcome of esophageal neuroendocrine tumor: A retrospective multicenter survey by the digestive endoscopy society of Taiwan. J Formos Med Assoc. 2021;120(1 Pt 2):508-514. doi: 10.1016/j.jfma.2020.06.024.

Gao R, Zhang Y, Wen XP, Fu J, Zhang GJ. Chemotherapy with cisplatin or carboplatin in combination with etoposide for small-cell esophageal cancer: a systemic analysis of case series. Dis Esophagus. 2014;27(8):764-9. doi: 10.1111/dote.12149.

Miao H, Li R, Chen D, Hu J, Chen Y, Wen Z. Survival outcomes and prognostic factors of primary small cell carcinoma of the esophagus. J Thorac Dis. 2021;13(5):2790-2802. doi: 10.21037/jtd-20-3334.

Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D’Amico TA, et al. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(12):1441-1464. doi: 10.6004/jnccn.2021.0058.

Mata A, Llacha J, Bordasa JM. Tratamiento paliativo del cáncer de esófago. Gastroenterología y Hepatología Continuada. 2007;6(2):68-71. doi: 10.1016/S1578-1550(07)74534-5.

Spaander M, Baron T, Siersema P, Fuccio L, Schumacher B, Escorsell À, et al. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2016;48(10):939-48. doi: 10.1055/s-0042-114210.